|
1
|
Shang L and Wang M: Molecular alterations
and clinical relevance in esophageal squamous cell carcinoma. Front
Med. 7:401–410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aghcheli K, Marjani HA, Nasrollahzadeh D,
Islami F, Shakeri R, Sotoudeh M, Abedi-Ardekani B, Ghavamnasiri MR,
Razaei E, Khalilipour E, et al: Prognostic factors for esophageal
squamous cell carcinoma-a population-based study in Golestan
Province, Iran, a high incidence area. PloS one. 6:e221522011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Golozar A, Beaty TH, Gravitt PE, Ruczinski
I, Qiao YL, Fan JH, Ding T, Tang ZZ, Etemadi A, Hu N, et al:
Oesophageal squamous cell carcinoma in high-risk Chinese
populations: Possible role for vascular epithelial growth factor A.
Eur J Cancer. 50:2855–2865. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee EJ, Lee BB, Kim JW, Shim YM, Hoseok I,
Han J, Cho EY, Park J and Kim DH: Aberrant methylation of fragile
histidine triad gene is associated with poor prognosis in early
stage esophageal squamous cell carcinoma. Eur J Cancer. 42:972–980.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee EJ, Lee BB, Han J, Cho EY, Shim YM,
Park J and Kim DH: CpG island hypermethylation of E-cadherin (CDH1)
and integrin alpha4 is associated with recurrence of early stage
esophageal squamous cell carcinoma. Int J Cancer. 123:2073–2079.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shimizu M, Zaninotto G, Nagata K, Graham
DY and Lauwers GY: Esophageal squamous cell carcinoma with special
reference to its early stage. Best Pract Res Clin Gastroenterol.
27:171–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen Y and Tseng SH: The potential of RECK
inducers as antitumor agents for glioma. Anticancer Res.
32:2991–2998. 2012.PubMed/NCBI
|
|
8
|
Clark JC, Thomas DM, Choong PF and Dass
CR: RECK-a newly discovered inhibitor of metastasis with prognostic
significance in multiple forms of cancer. Cancer Metastasis Rev.
26:675–683. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Masui T, Doi R, Koshiba T, Fujimoto K,
Tsuji S, Nakajima S, Koizumi M, Toyoda E, Tulachan S, Ito D, et al:
RECK expression in pancreatic cancer: Its correlation with lower
invasiveness and better prognosis. Clin Cancer Res. 9:1779–1784.
2003.PubMed/NCBI
|
|
10
|
Mao X, Liu L, Zhang B and Zhang D:
Reversion-inducing cysteine-rich protein with Kazal motifs gene
expression and its clinical significance in peripheral T-cell
lymphoma. Oncology Lett. 5:1867–1871. 2013.
|
|
11
|
Rahmah NN, Sakai K, Sano K and Hongo K:
Expression of RECK in endothelial cells of glioma: Comparison with
CD34 and VEGF expressions. J Neurooncol. 107:559–564. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alexius-Lindgren M, Andersson E, Lindstedt
I and Engstrom W: The RECK gene and biological malignancy-its
significance in angiogenesis and inhibition of matrix
metalloproteinases. Anticancer Res. 34:3867–3873. 2014.PubMed/NCBI
|
|
13
|
Li SL, Gao DL, Zhao ZH, Liu ZW, Zhao QM,
Yu JX, Chen KS and Zhang YH: Correlation of matrix
metalloproteinase suppressor genes RECK, VEGF and CD105 with
angiogenesis and biological behavior in esophageal squamous cell
carcinoma. World J Gastroenterol. 13:6076–6081. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee KJ, Lee KY and Lee YM: Downregulation
of a tumor suppressor RECK by hypoxia through recruitment of HDAC1
and HIF-1alpha to reverse HRE site in the promoter. Biochim Biophys
Acta. 1803:608–616. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jeon HW and Lee YM: Inhibition of histone
deacetylase attenuates hypoxia-induced migration and invasion of
cancer cells via the restoration of RECK expression. Mol Cancer
Ther. 9:1361–1370. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jeon HW, Lee KJ, Lee SH, Kim WH and Lee
YM: Attenuated expression and function of the RECK tumor suppressor
under hypoxic conditions is mediated by the MAPK signaling
pathways. Arch Pharm Res. 34:137–145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang HC, Cho CY and Hung WC:
Downregulation of RECK by promoter methylation correlates with
lymph node metastasis in non-small cell lung cancer. Cancer Sci.
98:169–173. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meng H, Cao Y, Qin J, Song X, Zhang Q, Shi
Y and Cao L: DNA methylation, its mediators and genome integrity.
Int J Biol Sci. 11:604–617. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang C, Ling Y, Zhang C, Xu Y, Gao L, Li
R, Zhu J, Fan L and Wei L: The silencing of RECK gene is associated
with promoter hypermethylation and poor survival in hepatocellular
carcinoma. Int J Biol Sci. 8:451–458. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kato K, Long NK, Makita H, Toida M,
Yamashita T, Hatakeyama D, Hara A, Mori H and Shibata T: Effects of
green tea polyphenol on methylation status of RECK gene and cancer
cell invasion in oral squamous cell carcinoma cells. Br J Cancer.
99:647–654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang HC, Cho CY and Hung WC: Silencing of
the metastasis suppressor RECK by RAS oncogene is mediated by DNA
methyltransferase 3b-induced promoter methylation. Cancer Res.
66:8413–8420. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang C, Xu Y, Zhao J, Fan L, Jiang G, Li
R, Ling Y, Wu M and Wei L: Elevated expression of the stem cell
marker CD133 associated with Line-1 demethylation in hepatocellular
carcinoma. Ann Surg Oncol. 18:2373–2380. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bais AJ, Gardner AE, McKenzie OL, Callen
DF, Sutherland GR and Kremmidiotis G: Aberrant CBFA2T3B gene
promoter methylation in breast tumors. Mol Cancer. 3:222004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang C, Guo X, Zhang L, Lu Z, Ma N, Cheng
Y, Shen F, Zhang B, Wu M and Wei L: Methylation-related silencing
of p14ARF gene correlates with telomerase activity and mRNA
expression of human telomerase reverse transcriptase in
hepatocellular carcinoma. J Surg Oncol. 98:462–468. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Noda M, Takahashi C, Matsuzaki T and
Kitayama H: What we learn from transformation suppressor genes:
Lessons from RECK. Future Oncol. 6:1105–1116. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou DN, Deng YF, Li RH, Yin P and Ye CS:
Concurrent alterations of RAGE, RECK, and MMP9 protein expression
are relevant to Epstein-Barr virus infection, metastasis and
survival in nasopharyngeal carcinoma. Int J Clin Exp Pathol.
7:3245–3254. 2014.PubMed/NCBI
|
|
28
|
Zhou X, Huang S, Jiang L, Zhang S, Li W,
Chen Z and Zhang D: Expression of RECK and MMP-2 in salivary
adenoid cystic carcinoma: Correlation with tumor progression and
patient prognosis. Oncology Lett. 7:1549–1555. 2014.
|
|
29
|
Yuki K, Yoshida Y, Inagaki R, Hiai H and
Noda M: E-cadherin-downregulation and RECK-upregulation are coupled
in the non-malignant epithelial cell line MCF10A but not in
multiple carcinoma-derived cell lines. Sci Rep. 4:45682014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Du YY, Dai DQ and Yang Z: Role of RECK
methylation in gastric cancer and its clinical significance. World
J Gastroenterol. 16:904–908. 2010.PubMed/NCBI
|
|
31
|
Pesta M, Kulda V, Topolcan O, Safranek J,
Vrzalova J, Cerny R and Holubec L: Significance of methylation
status and the expression of RECK mRNA in lung tissue of patients
with NSCLC. Anticancer Res. 29:4535–4539. 2009.PubMed/NCBI
|
